Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
about
Oligometastatic Prostate CancerSaracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceOligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.The biology and treatment of oligometastatic cancer.Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective StudyLipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.The oncologic role of local treatment in primary metastatic prostate cancer.New surgical approaches for clinically high-risk or metastatic prostate cancer.Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.STAT3 regulated ARF expression suppresses prostate cancer metastasis.Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression.Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome.Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients.Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases.The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.Case: Testicular oligometastasis from prostate cancer - Report of rare isolated recurrence after radiotherapy and intermittent androgen-deprivation therapy.(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy.Worth a local treatment? - Analysis of modern radiotherapy concepts for oligometastatic prostate cancerThe efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer
P2860
Q28075182-A089DFDA-33EE-4EE7-A777-B3FEB31B782AQ33426973-00A947BD-E0B0-461C-8CE0-AC85518504AAQ33789117-93C5E679-08D5-41C2-B929-5F5A16A621A6Q34748629-D47EF5DA-BA0C-4D08-854F-4CD1635683E7Q35832153-B7404130-F2AC-4BB0-BD90-6B0B7DE30C7DQ35987354-605EBEAE-4D39-4624-9D9E-67BFAF82F0C6Q36377961-8720324C-86CB-4426-8441-41B7F3CC0149Q36581142-AC83651A-3EC8-4AAB-A8A4-7ED8EF1C4ED9Q37665657-2E281F75-970B-49D2-9E2C-03E18CC7F99FQ38226522-25D5179B-6B21-4319-8494-2D7CC7A6A831Q38598269-834F2699-3CFE-46A7-9810-F60EFCF2FE3FQ38802235-87E12A43-5E57-4E49-B77F-B6A1E7316B51Q38850627-FF4E0DCC-B675-4EF3-8B37-AB1FDCCBE1F2Q38977428-906DA787-CA32-40B0-8312-78BEB23F54B3Q41566002-6B28B54D-F9A3-4BC0-9AE8-31041C65AB90Q41711657-148C639C-F626-41B1-B833-F1288A4BC323Q42785526-7FCA6CAD-706B-43E0-8574-666D903857FBQ47133990-7F23B9C2-C3E0-42B3-9D1E-E7DFEE614F5BQ47257677-9F02AA25-6404-4AA9-ACB1-890BDC58AE3AQ48262413-51B41E23-6383-442A-91F1-9A07F9B702ABQ48370281-83032D18-8A68-4EAA-A340-896E840B0BEBQ49084411-02AB7288-D102-4B50-A7B2-CAF4D115708DQ49368653-55F2F91F-76C8-4FF8-9FE3-ECC06E9896F8Q51715242-6972A6FC-F29E-435B-9A3F-EE05A4D4693BQ53093291-A35EB72D-0C1A-4D20-A94B-1479EBB2BB46Q53267613-65B6878C-05B8-44AA-92E9-AF79A225D602Q58706995-F89CBFB8-2AF7-4BF5-B240-336E27CB4705Q58802712-E3EDD794-31DC-4A3A-8296-F09F8D92C2C8
P2860
Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Prognostic factors influencing ...... th metastatic prostate cancer.
@en
Prognostic factors influencing ...... th metastatic prostate cancer.
@nl
type
label
Prognostic factors influencing ...... th metastatic prostate cancer.
@en
Prognostic factors influencing ...... th metastatic prostate cancer.
@nl
prefLabel
Prognostic factors influencing ...... th metastatic prostate cancer.
@en
Prognostic factors influencing ...... th metastatic prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Prognostic factors influencing ...... th metastatic prostate cancer.
@en
P2093
Bieke Lambert
Filip Ameye
Gert De Meerleer
Karel Decaestecker
Louke Delrue
Nicolaas Lumen
Valérie Fonteyne
P2860
P304
P356
10.1002/PROS.22750
P577
2014-02-01T00:00:00Z